Iberdomide

Iberdomide

Iberdomide is an immunomodulatory drug that is being investigated for its potential use in the treatment of various autoimmune diseases and hematologic malignancies. It is a derivative of thalidomide and belongs to a class of drugs known as cereblon (CRBN) modulators.

Mechanism of Action

Iberdomide exerts its effects by binding to the cereblon protein, which is part of the E3 ubiquitin ligase complex. This binding leads to the degradation of specific target proteins, including Ikaros (IKZF1) and Aiolos (IKZF3), which are transcription factors involved in the regulation of immune responses. By degrading these proteins, iberdomide modulates the activity of T cells and B cells, thereby exerting its immunomodulatory effects.

Clinical Development

Iberdomide is currently undergoing clinical trials for the treatment of various conditions, including multiple myeloma, systemic lupus erythematosus (SLE), and other autoimmune disorders. Early-phase clinical trials have shown promising results, with iberdomide demonstrating efficacy in reducing disease activity and improving clinical outcomes in patients with these conditions.

Side Effects

As with other immunomodulatory drugs, iberdomide may cause a range of side effects. Common side effects observed in clinical trials include fatigue, nausea, diarrhea, and cytopenias such as neutropenia and thrombocytopenia. Patients receiving iberdomide should be monitored for these potential adverse effects.

Regulatory Status

As of now, iberdomide has not yet received regulatory approval for clinical use. It remains an investigational drug, and its safety and efficacy continue to be evaluated in ongoing clinical trials.

See Also

• Thalidomide
• Lenalidomide
• Pomalidomide
• Immunomodulatory drugs
• Multiple myeloma
• Systemic lupus erythematosus

References

‎